| abstract |
The present description relates, in general, to the field of phosphodiesterase 10 (PDE10) enzyme inhibition by means of the cinnoline compounds of formula (I) and (II) (See Formulas I and II) where R'-R3 and R15 -R18 are as defined herein. Moreover, the present invention provides the methods for synthesizing compounds with such activity and selectivity, as well as the methods of and corresponding to pharmaceutical compositions for the treatment of a patient, for example mammals, including humans, in need of inhibition of the PDE. The treatment is preferably for a disease state that involves elevated concentrations of intracellular PDE10 or decreased levels of CAMP and / or cGMP, for example, includes neurological or psychiatric syndromes, especially those states associated with psychosis, more especially schizophrenia or bipolar disorder, obsessive-compulsive disorder and / or Parkinson's disease. In particular, psychosis, obsessive compulsive disorder and / or Parkinson's disease are due at least in part to the catabolism of the intracellular levels of cAMP and / or cGMP by PDE10 enzymes, or where a deteriorated state like this can be improved increasing the concentrations of cAMP and / or cGMP. |